Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) Shorts Increased By 0.91% As Of Apr 12, 2019

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Corporate Logo

Change of 0.91% for Lexicon Pharmaceuticals Inc (NASDAQ:LXRX)’s shorted shares was noted. FINRA published shorted shares of LXRX’s total 8.00M shares. The up change of 0.91% from 7.93M shares was reported. Previous LXRX’s position will need 15 days to recover. It has 537,100 average volume. Lexicon Pharmaceuticals Inc’s shorted shares float is 7.58%.

LXRX reached $5.95 during the last trading session after $0.26 change.Currently Lexicon Pharmaceuticals, Inc. is downtrending after 20.39% change in last April 12, 2018. LXRX has also 209,361 shares volume. LXRX underperformed by 24.76% the S&P 500.

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products for the treatment of human diseases.The company has $632.32 million market cap. The firm offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with SSA therapy in adults.Last it reported negative earnings. The Company’s orally-delivered small molecule drug candidates under development comprise Sotagliflozin that is in Phase 3 clinical trials for use in the treatment of type 1 and type 2 diabetes; LX2761, which is in Phase 1 development for use in the treatment of diabetes; and LX9211 for use as a treatment for neuropathic pain.

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Ratings Coverage

In total 3 analysts cover Lexicon Pharmaceuticals (NASDAQ:LXRX). “Buy” rating has 3, “Sell” are 0, while 0 are “Hold”. 100% are bullish. 10 are the (NASDAQ:LXRX)’s analyst reports since November 2, 2018 according to StockzIntelligence Inc. The stock rating was maintained by Wedbush with “Buy” on Friday, March 15. On Thursday, March 14 the firm has “Sell” rating given by Gabelli. On Friday, November 2 the stock of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) has “Buy” rating given by Citigroup. The stock rating was maintained by Wedbush with “Buy” on Monday, March 4. The stock rating was maintained by Wedbush with “Buy” on Monday, March 25. On Monday, March 25 Stifel Nicolaus maintained Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) with “Buy” rating.

For more Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) news published recently go to: Benzinga.com, Nasdaq.com, Benzinga.com, Nasdaq.com or Nasdaq.com. The titles are as follows: “Benzinga’s Top Upgrades, Downgrades For March 14, 2019 – Benzinga” published on March 14, 2019, “Health Care Sector Update for 03/13/2019: NVCN, CASI, LXRX, JNJ, PFE, ABT, MRK, AMGN – Nasdaq” on March 13, 2019, “60 Biggest Movers From Friday – Benzinga” with a publish date: March 25, 2019, “AstraZeneca’s Forxiga Gets EC Approval for Type-I Diabetes – Nasdaq” and the last “AstraZeneca’s Forxiga Gets Nod in Japan for Type I Diabetes – Nasdaq” with publication date: March 28, 2019.

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.